[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$cnta](/topic/$cnta)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"End of Day Laggers $RAPT $DGNX $CRML $BTQ $BKKT $LVWR $INV $QBTS $CNTA $LAES $CELC $VSTM $IMAB $GKOS $NMG"  
[X Link](https://x.com/DayTraderTeam/status/1980378625221505440) [@DayTraderTeam](/creator/x/DayTraderTeam) 2025-10-20T21:00Z XXX followers, XXX engagements


"$NVDA $TSM $PLTR $AI $RKLB $RDW $ASTS $IONQ $RGTI $QBTS $DRI $OKLO $LZRFY $VKTX $SMMT $BBSEY $TTVSY $ACN $CNTA $GEO $ANF $DOCS $BILL $APGE $JWN $POWL $GEV $LUMN $STRL $UAL $ERJ $AGYS $CLBT $UEC $ELP $JBLU $NSIT $NWE $ALK"  
[X Link](https://x.com/linhnguyen64143/status/1980371311873650808) [@linhnguyen64143](/creator/x/linhnguyen64143) 2025-10-20T20:31Z XX followers, XXX engagements


"Mizuho reiterated $ALKS Outperform/$40 $CNTA $AXSM Mizuho said in its note: We preview 3Q25 for ALKS and expect slightly above-consensus 3Q25 revenues of $358M (vs. $355M Bloomberg cons) and GAAP EPS of $XXXX (vs. $XXXX cons) driven by potentially above-consensus Aristada and Lybalvi sales. That said we believe investors are likely more focused on the Vibance-2 Phase X readout for alixorexton (ALKS-2680) in narcolepsy type X (NT2) this fall. Heading into this readout we believe the key concerns are potential for high visual AE rates as Vibrance-2 evaluates higher doses (10 XX 18mg) than 8mg"  
[X Link](https://x.com/Quantumup1/status/1975893719363506397) [@Quantumup1](/creator/x/Quantumup1) 2025-10-08T11:59Z 3849 followers, 1639 engagements


"$QURE Stock: uniQure (QURE $57.92) was a top quarterly gainer rising +281.35%. $ADMA $SLNO $CNTA"  
[X Link](https://x.com/Tickeron/status/1975861237805420709) [@Tickeron](/creator/x/Tickeron) 2025-10-08T09:50Z 19.4K followers, XXX engagements